Win Tay Za Kyi, Simms Kate, Thinn Myint Myint, Tin Khaing Nwe, Aung Soe, Feletto Eleonora, Bateson Deborah, Canfell Karen
School of Public Health, The University of Sydney, Camperdown, NSW, Australia.
Department of Gynaecologic Oncology, Central Women Hospital, Yangon, Myanmar.
J Epidemiol Glob Health. 2025 Jun 25;15(1):89. doi: 10.1007/s44197-025-00436-4.
Myanmar is estimated to have one of the highest cervical cancer incidence and mortality rates in Asia. There have been limited screening and treatment services for cervical cancer in Myanmar. In this context, to support cervical cancer elimination, understanding the current burden of cervical cancer in the country is crucial. This review aims to synthesize the evidence on the epidemiology of cervical cancer in Myanmar.
We used the Joanna Briggs Institute approach for systematic review of observational epidemiological studies to conduct a comprehensive review of burden of human papillomavirus (HPV), precancerous cervical lesions, key co-factors and cervical cancer in Myanmar. Embase, Global Health, Medline, and local databases were searched to May 31, 2024.
Regional population-based cancer registries from Nay Pyi Taw and Yangon reported age-standardized incidence rates of cervical cancer of 19.3 (in 2018) and 14.1 (during 2013–2017) per 100 000 females, respectively. Meta-analyses were conducted to estimate HPV prevalence among the general female population (18–65 years) as 4% [95% Confidence Interval (CI): 3–5%] in the community-based and 11% [95% CI: (4–21%)] in outpatient clinic screening. Among HIV-positive women, HPV prevalence was reported at 30.1%. The most common HPV types in HPV-positive cervical cancers were HPV 16 (60–85.7%) and HPV 18 (14.8–20%). The prevalence of key co-factors included HIV infection (0.7% in the general female population and 8.3% in female sex workers), tobacco use in females (smoking: 8.4% and smokeless: 24.1%), high parity (4.99 births per married woman) and early aged pregnancy (33 births per 1000 adolescent females).
The cervical cancer incidence rates reported from two regional cancer registries in Myanmar are high relative to those reported in countries across Asia. An estimated one in nine to one in 25 women in Myanmar is infected with HPV, which is broadly concordant with regional estimates. A high prevalence of key co-factors for cervical cancer, combined with limited screening and treatment services, may increase the risk of progression to invasive cancers among HPV infected women. Consequently, Myanmar is likely to bear a substantial burden of cervical cancer.
The online version contains supplementary material available at 10.1007/s44197-025-00436-4.
据估计,缅甸是亚洲宫颈癌发病率和死亡率最高的国家之一。缅甸宫颈癌的筛查和治疗服务有限。在此背景下,为支持消除宫颈癌,了解该国目前的宫颈癌负担至关重要。本综述旨在综合缅甸宫颈癌流行病学的证据。
我们采用乔安娜·布里格斯研究所的方法对观察性流行病学研究进行系统综述,以全面回顾缅甸人乳头瘤病毒(HPV)、宫颈癌前病变、关键协同因素和宫颈癌的负担。检索了Embase、全球健康、Medline和当地数据库,截至2024年5月31日。
内比都和仰光基于地区人群的癌症登记处报告,宫颈癌的年龄标准化发病率分别为每10万名女性19.3例(2018年)和14.1例(2013 - 2017年期间)。进行荟萃分析以估计一般女性人群(18 - 65岁)中HPV的患病率,社区为4% [95%置信区间(CI):3 - 5%],门诊筛查为11% [95% CI:(4 - 21%)]。在HIV阳性女性中,HPV患病率报告为30.1%。HPV阳性宫颈癌中最常见的HPV类型是HPV 16(60 - 85.7%)和HPV 18(14.8 - 20%)。关键协同因素的患病率包括HIV感染(一般女性人群中为0.7%,女性性工作者中为8.3%)、女性吸烟(吸烟:8.4%,无烟:24.1%)、高生育次数(已婚女性平均生育4.99胎)和早孕(每1000名青春期女性生育33胎)。
缅甸两个地区癌症登记处报告的宫颈癌发病率相对于亚洲其他国家较高。估计缅甸每九至二十五名女性中就有一人感染HPV,这与地区估计大致一致。宫颈癌关键协同因素的高患病率,加上筛查和治疗服务有限,可能会增加HPV感染女性发展为浸润性癌症的风险。因此,缅甸可能承受着巨大的宫颈癌负担。
在线版本包含可在10.1007/s44197 - 025 - 00436 - 4获取的补充材料。